
Menu




Eureka Therapeutics Announces Publication of Armored T-Cell Proof-of-Concept Study in Nature Biotechnology
August 16, 2018
EMERYVILLE, CA, USA, August 16, 2018 – Eureka Therapeutics, Inc., a clinical stage biopharmaceutical company with the goal of curing cancer by developing novel T-cell therapies


Eureka Therapeutics Announces that Boehringer Ingelheim is Exercising an Option to License Novel TCR Mimic (TCRm) Antibodies
July 17, 2018
EMERYVILLE, CA, USA , July 17, 2018 – Eureka Therapeutics Inc. announced today that Boehringer Ingelheim has elected to exercise an option for the exclusive
Eureka Expands Scientific Advisory Board Members with Addition of Cytokine Release Syndrome (CRS) Experts Stephan A. Grupp, M.D., Ph.D. and Cameron J. Turtle, MBBS, Ph.D., FRACP, FRCPA
July 16, 2018
Emeryville, California, July 16, 2018 – Eureka Therapeutics, Inc., a clinical stage biopharmaceutical company with the goal of curing cancer by developing novel T-cell therapies


